The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.

6 , 19 , 28 These data and data from the therapy indicate a clear trend favouring immunotherapy in the first‐line setting, with an increase of ~20% in the 3‐year OS rate.

also in 19,460 other papers

Only a statistical trend towards difference in serum LDH level and metastatic site involvement was observed when comparing patients with CR and PD.

also in 2,798 other papers